Letters to the Editor

Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial

Department of Clinical Haematology, The Alfred Hospital, Melbourne, Australia; Australian Centre for Blood Diseases, Monash University, Melbourne
Weill Cornell Medicine, New York, NY, USA; New York Presbyterian Hospital, New York, NY
Hematology, Hopital Saint-Louis, Assistance Publique – Hopitaux de Paris (AP-HP), Paris, France; Institut de Recherche Saint-Louis, Universite Paris Cite, Paris
Department of Internal Medicine III, Ulm University Hospital, Ulm
Princess Margaret Cancer Centre, Toronto, ON
Hospital Universitario y Politecnico La Fe, Valencia
AZ Sint-Jan Brugge-Oostende AV, Bruges
RM Gorbacheva Research Institute, Pavlov University, St. Petersburg
Bristol Myers Squibb, Summit, NJ
Bristol Myers Squibb, Summit, NJ
Bristol Myers Squibb, Summit, NJ, USA; University of Kansas Cancer Center, Kansas City, KS
Bristol Myers Squibb, Summit, NJ
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
Vol. 108 No. 10 (2023): October, 2023 https://doi.org/10.3324/haematol.2022.282296